je.st
news
Tag: hepatitis
In Animal Model Of Hepatitis B Infection, New Drug Stimulates Immune System To Kill Infected Cells
2013-04-30 12:01:53| Biotech - Topix.net
A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.
Market District Offers Free Hepatitis C Screenings
2013-04-30 11:41:27| Grocery - Topix.net
Giant Eagle and the American Liver Foundation have partnered to offer a series of free rapid hepatitis C screenings at four Pittsburgh-area Giant Eagle Pharmacies, including the South Hills Market District in Bethel Park.
Tags: free
offers
market
district
Gilead-Bristol Hepatitis C Drug Combo Cures 100% in Study
2013-04-28 01:32:43| Biotech - Topix.net
A combination of hepatitis C drugs from Gilead Sciences Inc. and Bristol-Myers Squibb Co.
Tags: study
drug
combo
hepatitis
New drug stimulates immune system to kill infected cells in animal model of hepatitis B infection
2013-04-27 21:23:10| Biotech - Topix.net
In a study conducted at Texas Biomed's Southwest National Primate Research Center, researchers found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in chimpanzees chronically infected with hepatitis B virus .
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress
2013-04-23 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language: English Contact HTML: MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
updated
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] next »